Pricing Log in Create free account

AbCellera Biologics Inc. (ABCL) vs Telix Pharmaceuticals Limited (TLX)

AbCellera Biologics Inc. and Telix Pharmaceuticals Limited are both Biotechnology companies. AbCellera Biologics Inc. is the larger, with a market value of $4.1B against $3.6B — 1.1× the size. Across the 9 metrics below, Telix Pharmaceuticals Limited leads on 5 and AbCellera Biologics Inc. on 4.

Valuation

Metric ABCL TLX Biotechnology median
P/E n/m — 8.50
P/S 54.49 — 9.71
P/B 4.02 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 46.00 n/m 9.21
Earnings yield (4.58%) — (33.15%)
Free cash flow yield (3.41%) 0.00% (25.50%)

Profitability

Metric ABCL TLX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (340.25%) — 0.00%
Net margin (248.82%) — 0.00%
Free cash flow margin (180.84%) 0.00% 0.00%
Return on equity (17.30%) 0.00% (56.36%)
Return on assets (12.15%) 0.00% (48.04%)
Return on invested capital (42.52%) 0.00% 0.00%

Growth

Metric ABCL TLX Biotechnology median
Revenue growth (TTM) 101.29% — 6.02%
EPS growth (last fiscal year) 10.91% (120.00%) 30.26%
Revenue growth, 5-year CAGR (20.27%) — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ABCL TLX Biotechnology median
Debt to equity 0.00 1.18 0.00
Current ratio 12.77 2.01 4.72
Net debt to EBITDA 2.97 6.25 0.96

Dividend

Metric ABCL TLX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ABCL TLX Biotechnology median
Market cap 4.11b 3.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack